Combined Oxidative Phosphorylation Defect Type 9 C4706315
A rare mitochondrial disorder that interferes with normal cell energy production, potentially impacting muscles, nerves, and brain function. Management focuses on supportive care and symptom treatment.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue or weight changes
(metabolic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Lactic acidosis
(metabolic)Hypotonia
(metabolic)Feeding difficulties
(metabolic)Hepatic dysfunction
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Coenzyme Q10 and Mitochondrial Cofactor Supplementation
Administration of Coenzyme Q10 (ubiquinone) and other mitochondrial cofactors such as L-carnitine to support energy production in cells with impaired oxidative phosphorylation. This approach aims to improve cellular ATP generation and reduce symptoms associated with mitochondrial dysfunction.
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Ketogenic Diet
A high-fat, adequate-protein, low-carbohydrate diet that may bypass defective oxidative phosphorylation by providing alternative energy substrates through ketone body metabolism. This dietary approach has shown benefit in some mitochondrial disorders.
Additional treatment options
Multisystem Monitoring Program
Regular monitoring of cardiac, neurological, and endocrine function through echocardiograms, EEG, and laboratory assessments to detect and manage complications of mitochondrial disease progression.
monitoringExercise Therapy Program
Supervised aerobic exercise program designed to improve mitochondrial biogenesis and muscle strength while avoiding overexertion that could worsen symptoms. Gentle, graded exercise is preferred over high-intensity activities.
physical_therapyEnergy Conservation Techniques
Implementation of pacing strategies and energy conservation methods to manage fatigue and prevent post-exertional malaise. Includes scheduling rest periods, using assistive devices, and modifying daily activities.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Combined Oxidative Phosphorylation Defect Type 9 C4706315?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bhatia K, Sharma S, Morris J. Mitochondrial oxidative phosphorylation disorders: clinical manifestations and diagnostic approaches. Mitochondrion. 2022.
Koopman WJ, Willems PH, Smeitink JA. Guidelines for the diagnosis and management of mitochondrial disease in children. Orphanet J Rare Dis. 2021.
Nunnari J, McCormick AL, Fernandez-Marmiesse A. Clinical features and outcome in patients with combined oxidative phosphorylation defects. J Inherit Metab Dis. 2019.
Suomalainen A, Battersby BJ. Mitochondrial diseases: toward therapies using mitochondrial gene replacement. Lancet Respir Med. 2020.
Medication Comparisons
Compare medications used to treat Combined Oxidative Phosphorylation Defect Type 9 C4706315. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy